Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Misses Expectations By $0.06 EPS

Posted by Brian Himes on Nov 4th, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) posted its quarterly earnings data on Monday. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06), FiscalAI reports. Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the firm posted $4.80 earnings per share. The business’s revenue was up 11.8% on a year-over-year basis.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

Third-quarter revenue rose 12% year over year, and Vertex raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion, reflecting continued CF performance and growing contributions from CASGEVY, JOURNAVX, and PALSONIFY.
Commercial momentum remained strong across newer products: ALYFTREK generated $706 million in quarterly sales, CASGEVY revenue increased 30% sequentially to $99 million, JOURNAVX prescriptions surpassed 750,000, and PALSONIFY reached $10 million in September.
Vertex is preparing for the November 30 FDA decision on povetacicept in IgA nephropathy, highlighting its expected efficacy, tolerability, and once-monthly at-home auto-injector; the company also completed enrollment in the pivotal AMPLITUDE study of inaxaplin and expects interim data in early 2027.
The company advanced its pipeline by prioritizing VX-017, an allogeneic, off-the-shelf islet cell therapy for type 1 diabetes, with phase I/II dosing underway and a goal of entering pivotal development next year; it also reported encouraging early results for the VX-828 next-generation CF corrector.
Vertex increased full-year non-GAAP operating expense guidance to approximately $6 billion, including Crinetics-related costs, and incurred roughly $50 million in third-quarter financing and transaction costs; the Crinetics acquisition also added $4.5 billion in term loans at approximately 4.8% interest.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $530.76 on Wednesday. Vertex Pharmaceuticals has a 52-week low of $403.16 and a 52-week high of $568.67. The stock has a market capitalization of $134.71 billion, a price-to-earnings ratio of 34.15, a price-to-earnings-growth ratio of 2.65 and a beta of 0.28. The company has a fifty day moving average of $522.98 and a 200-day moving average of $480.37.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

Positive Sentiment: Third-quarter revenue increased 12% year over year to $3.44 billion, topping estimates as cystic fibrosis treatments and newer products, including CASGEVY, contributed to growth. Vertex also raised its 2026 revenue outlook to $13.2 billion–$13.3 billion. Vertex third-quarter results
Positive Sentiment: Several analysts raised price targets after the results, including Goldman Sachs, which lifted its target to $725 and maintained a buy rating. Goldman Sachs rating update
Neutral Sentiment: Investors are also watching povetacicept, Vertex’s potential IgA nephropathy treatment. Executives expressed confidence ahead of an FDA decision, but the drug’s approval and commercial opportunity remain future catalysts. Vertex discusses kidney drug
Negative Sentiment: Adjusted earnings of $4.76 per share missed the $4.82 consensus estimate. Investors also appeared concerned that the raised revenue forecast was modest relative to expectations, while light JOURNAVX sales and acquisition and launch expenses weighed on the outlook for profit growth. Vertex earnings and outlook

Analysts Set New Price Targets

VRTX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a research note on Tuesday. Scotiabank lifted their price target on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. UBS Group upped their price objective on Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a report on Tuesday. Jefferies Financial Group increased their price objective on Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Finally, TD Cowen increased their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $596.11.

View Our Latest Stock Analysis on VRTX

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

Earnings History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.